Department of Oncology, No. 303 Hospital of Chinese People's Liberation Army, Nanning, Guangxi 530021, China.
Department of Medical Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China.
Biomed Pharmacother. 2018 Oct;106:593-598. doi: 10.1016/j.biopha.2018.06.077. Epub 2018 Jul 11.
Non-small cell lung cancer (NSCLC) is one of the most prevailing malignancies worldwide. It has been previously shown that wogonoside exerts anti-tumor activities in various kinds of human cancers. But its role in NSCLC remains elusive. In the present study, we determined the anti-tumor effect of wogonoside in human NSCLC A549 cells. We found that wogonoside effectively inhibits A549 cell viability through inducing cell cycle arrest and apoptosis. Moreover, administration of wogonoside by intraperitoneal injection inhibits the growth of A549 cell xenografts in athymic nude mice. Additionally, mitochondrial membrane potential was disrupted and cytochrome c was released to cytosol in the wogonoside-treated A549 cells. Finally, we found that AMPK/mTOR signaling might be implicated in the anti-NSCLC efficacy of wogonoside. Therefore, we may assume that wogonoside may be considered as a potential therapeutic agent for the treatment of NSCLC.
非小细胞肺癌（NSCLC）是全球最常见的恶性肿瘤之一。先前的研究表明，甘草苷在各种人类癌症中具有抗肿瘤活性。但它在非小细胞肺癌中的作用仍不清楚。在本研究中，我们确定了甘草苷对人非小细胞肺癌 A549 细胞的抗肿瘤作用。我们发现，甘草苷通过诱导细胞周期停滞和细胞凋亡，有效地抑制 A549 细胞的活力。此外，腹腔注射甘草苷可抑制裸鼠异种移植 A549 细胞的生长。此外，在甘草苷处理的 A549 细胞中，线粒体膜电位被破坏，细胞色素 c 释放到细胞质中。最后，我们发现 AMPK/mTOR 信号通路可能与甘草苷的抗 NSCLC 疗效有关。因此，我们可以假设甘草苷可能被认为是治疗 NSCLC 的潜在治疗剂。
